We propose a Bayesian hierarchical method for combining in silico and in vivo data onto an augmented clinical trial with binary end points. The joint posterior distribution from the in silico experiment is treated as a prior, weighted by a measure of compatibility of the shared characteristics with the in vivo data. We also formalise the contribution and impact of in silico information in the augmented trial. We illustrate our approach to inference with in silico data from the UISS-TB simulator, a bespoke simulator of virtual patients with tuberculosis infection, and synthetic physical patients from a clinical trial
Leveraging preclinical animal data for a phase I oncology trial is appealing yet challenging. In thi...
Objective: To show how a simple Bayesian analysis method can be used to improve the evidence base in...
Neste artigo, apresentamos estimadores bayesianos para a prevalência de tuberculose usando métodos c...
open12siBACKGROUND: Tuberculosis (TB) represents a worldwide cause of mortality (it infects one thir...
Background The STriTuVaD project, funded by Horizon 2020, aims to test through a Phase IIb clinic...
Background In 2018, about 10 million people were found infected by tuberculosis, with approximate...
Tuberculosis is one of the leading causes of death in several developing countries and a public heal...
University of Minnesota Ph.D. dissertation. August 2015. Major: Biostatistics. Advisor: Joseph Koopm...
Tuberculosis (TB) accounts for over 1 million deaths each year, despite effective treatment regimen...
Background: Given the success of recent platform trials for COVID-19, Bayesian statistical methods h...
Perhaps the most valuable contribution of Bayesian methods to health care evaluation involves study ...
We propose a Bayesian approach for estimating branching tree mixture models to compare drug-resistan...
In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Now...
In Tuberculosis (TB), given the complexity of its transmission dynamics, observations of reduced epi...
In this paper we present an extension of an automata approach proposed by S. Blower (1998) to descri...
Leveraging preclinical animal data for a phase I oncology trial is appealing yet challenging. In thi...
Objective: To show how a simple Bayesian analysis method can be used to improve the evidence base in...
Neste artigo, apresentamos estimadores bayesianos para a prevalência de tuberculose usando métodos c...
open12siBACKGROUND: Tuberculosis (TB) represents a worldwide cause of mortality (it infects one thir...
Background The STriTuVaD project, funded by Horizon 2020, aims to test through a Phase IIb clinic...
Background In 2018, about 10 million people were found infected by tuberculosis, with approximate...
Tuberculosis is one of the leading causes of death in several developing countries and a public heal...
University of Minnesota Ph.D. dissertation. August 2015. Major: Biostatistics. Advisor: Joseph Koopm...
Tuberculosis (TB) accounts for over 1 million deaths each year, despite effective treatment regimen...
Background: Given the success of recent platform trials for COVID-19, Bayesian statistical methods h...
Perhaps the most valuable contribution of Bayesian methods to health care evaluation involves study ...
We propose a Bayesian approach for estimating branching tree mixture models to compare drug-resistan...
In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Now...
In Tuberculosis (TB), given the complexity of its transmission dynamics, observations of reduced epi...
In this paper we present an extension of an automata approach proposed by S. Blower (1998) to descri...
Leveraging preclinical animal data for a phase I oncology trial is appealing yet challenging. In thi...
Objective: To show how a simple Bayesian analysis method can be used to improve the evidence base in...
Neste artigo, apresentamos estimadores bayesianos para a prevalência de tuberculose usando métodos c...